Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration

Gut

Volumn 66, Issue 10, 2017, Pages 1818-1828

  Alvarez Sola, Gloria ^a   Uriarte, Iker ^a   Latasa, M Ujue ^a   Fernandez Barrena, Maite G ^a   Urtasun, Raquel ^a   Elizalde, Maria ^a   Barcena Varela, Marina ^a   Jiménez, Maddalen ^a   Chang, Haisul C ^a   Barbero, Roberto ^a   Catalán, Victoria ^b   Rodríguez, Amaia ^b   Frühbeck, Gema ^b   Gallego Escuredo, José M ^c   Gavaldà Navarro, Aleix ^c   Villarroya, Francesc ^c   Rodriguez Ortigosa, Carlos M ^a   Corrales, Fernando J ^a   Prieto, Jesus ^a   Berraondo, Pedro ^a   Berasain, Carmen ^a   Avila, Matias A ^a   more..

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cholestasis; Fatty Liver; Growth Factors; Liver Failure; Liver Regeneration

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; APOLIPOPROTEIN A1; BILE ACID; CASPASE 3; CD36 ANTIGEN; CHOLESTEROL 7ALPHA MONOOXYGENASE; FATTY ACID TRANSPORTER 4; FIBAPO; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; LIVER PROTECTIVE AGENT; MESSENGER RNA; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; RECOMBINANT FIBROBLAST GROWTH FACTOR 19; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 15, MOUSE; HYBRID PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DB/DB MOUSE; DRUG BLOOD LEVEL; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; GENE EXPRESSION; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUM; LIPID DIET; LIPID METABOLISM; LIVER FAILURE; LIVER PROTECTION; LIVER REGENERATION; MAJOR CLINICAL STUDY; MALE; MOUSE; NCI-H69 CELL LINE; NONHUMAN; OBESITY; PARTIAL HEPATECTOMY; PLASMA HALF LIFE; PRIORITY JOURNAL; SURVIVAL RATE; TISSUE DISTRIBUTION; ANIMAL; CELL LINE; DRUG EFFECTS; GENETICS; HALF LIFE TIME; LIVER; LIVER RESECTION; METABOLISM; MOUSE MUTANT; PROTEIN SYNTHESIS; UPREGULATION;

ANIMALS; APOLIPOPROTEIN A-I; APOPTOSIS; BILE ACIDS AND SALTS; CELL LINE; DIET, HIGH-FAT; ENDOPLASMIC RETICULUM STRESS; FATTY LIVER; FIBROBLAST GROWTH FACTORS; HALF-LIFE; HEPATECTOMY; HUMANS; ILEUM; LIPID METABOLISM; LIVER; LIVER REGENERATION; MALE; MICE; MICE, OBESE; PALMITIC ACID; PPAR GAMMA; PROTEIN BIOSYNTHESIS; RECOMBINANT FUSION PROTEINS; UP-REGULATION;

EID: 85011051989     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-312975     Document Type: Article

References (53)

1. Hardy T, Oakley F, Anstee QM, et al. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annu Rev Pathol 2016;11:451-96.
2. Mota M, Banini BA, Cazanave SC, et al. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metab Clin Exp 2016;65:1049-61.
3. Kumashiro N, Erion DM, Zhang D, et al. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA 2011;108:16381-5.
4. Bechmann LP, Kocabayoglu P, Sowa JP, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013;57:1394-406.
5. Aranha MM, Cortez-Pinto H, Costa A, et al. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol 2008;20:519-25.
6. Natarajan SK, Ingham SA, Mohr AM, et al. Saturated free fatty acids induce cholangiocyte lipoapoptosis. Hepatology 2014;60:1942-56.
7. Kir S, Beddow SA, Samuel VT, et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011;331:1621-4.
8. Jahn D, Rau M, Hermanns HM, et al. Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine Growth Factor Rev 2015;26:625-35.
9. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: From feast to famine. Genes Dev 2012;26:312-24.
10. Tomlinson E, Fu L, John L, et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002;143:1741-7.
11. Fu L, John LM, Adams SH, et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004;145:2594-603.
12. Schreuder TCMA, Marsman HA, Lenicek M, et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 2010;298:G440-5.
13. McCormack L, Petrowsky H, Jochum W, et al. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: A matched case-control study. Ann Surg 2007;245:923-30.
14. Kele PG, van der Jagt EJ, Gouw ASH, et al. The impact of hepatic steatosis on liver regeneration after partial hepatectomy. Liver Int 2013;33:469-75.
15. Hoppe S, von Loeffelholz C, Lock JF, et al. Nonalcoholic steatohepatits and liver steatosis modify partial hepatectomy recovery. J Invest Surg 2015;28:24-31.
16. Cho JY, Suh KS, Lee HW, et al. Hepatic steatosis is associated with intrahepatic cholestasis and transient hyperbilirubinemia during regeneration after living donor liver transplantation. Transpl Int 2006;19:807-13.
17. Yang SQ, Lin HZ, Mandal AK, et al. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: Implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 2001;34:694-706.
18. Murata H, Yagi T, Iwagaki H, et al. Mechanism of impaired regeneration of fatty liver in mouse partial hepatectomy model. J Gastroenterol Hepatol 2007;22:2173-80.
19. Hamano M, Ezaki H, Kiso S, et al. Lipid overloading during liver regeneration causes delayed hepatocyte DNA replication by increasing ER stress in mice with simple hepatic steatosis. J Gastroenterol 2014;49:305-16.
20. Inaba Y, Furutani T, Kimura K, et al. Growth arrest and DNA damage-inducible 34 regulates liver regeneration in hepatic steatosis in mice. Hepatology 2015;61:1343-56.
21. Uriarte I, Fernandez-Barrena MG, Monte MJ, et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 2013;62:899-910.
22. Kong B, Huang J, Zhu Y, et al. Fibroblast growth factor 15 deficiency impairs liver regeneration in mice. Am J Physiol Gastrointest Liver Physiol 2014;306:G893-902.
23. Padrissa-Altés S, Bachofner M, Bogorad RL, et al. Control of hepatocyte proliferation and survival by Fgf receptors is essential for liver regeneration in mice. Gut 2015;64:1444-53.
24. Luo J, Ko B, Elliott M, et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med 2014;6:247ra100.
25. Fioravanti J, González I, Medina-Echeverz J, et al. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties. Hepatology 2011;53:1864-73.
26. Uriarte I, Latasa MU, Carotti S, et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int J Cancer 2015;136:2469-75.
27. Lee YJ, Ko EH, Kim JE, et al. Nuclear receptor PPAR-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis. Proc Natl Acad Sci USA 2012;109:13656-61.
28. Gallego-Escuredo JM, Gómez-Ambrosi J, Catalan V, et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes (Lond) 2015;39:121-9.
29. Leamy AK, Egnatchik RA, Young JD. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog Lipid Res 2013;52:165-74.
30. Kammoun HL, Chabanon H, Hainault I, et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 2009;119:1201-15.
31. Yamagishi N, Ueda T, Mori A, et al. Decreased expression of endoplasmic reticulum chaperone GRP78 in liver of diabetic mice. Biochem Biophys Res Commun 2012;417:364-70.
32. Shimizu M, Li J, Maruyama R, et al. FGF19 (fibroblast growth factor 19) as a novel target gene for activating transcription factor 4 in response to endoplasmic reticulum stress. Biochem J 2013;450:221-9.
33. Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1 Pathway. Cell Metab 2011;13: 729-38.
34. Seeßle J, Liebisch G, Schmitz G, et al. Palmitate activation by fatty acid transport protein 4 as a model system for hepatocellular apoptosis and steatosis. Biochim Biophys Acta 2015;1851:549-65.
35. Fon Tacer K, Bookout AL, Ding X, et al. Research resource: Comprehensive expression Atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010;24:2050-64.
36. Zweers SJLB, Booij KAC, Komuta M, et al. The human gallbladder secretes fibroblast growth factor 19 into bile: Towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 2012;55:575-83.
37. Avila MA, Berasain C, Torres L, et al. Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol 2000;33:907-14.
38. Elizalde M, Urtasun R, Azkona M, et al. Splicing regulator SLU7 is essential for maintaining liver homeostasis. J Clin Invest 2014;124:2909-20.
39. Markan KR, Potthoff MJ. Metabolic fibroblast growth factors (FGFs): Mediators of energy homeostasis. Semin Cell Dev Biol 2016;53:85-93.
40. Bhatnagar S, Damron HA, Hillgartner FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem 2009;284:10023-33.
41. Yu JH, Song SJ, Kim A, et al. Suppression of PPAR-mediated monoacylglycerol O-acyltransferase 1 expression ameliorates alcoholic hepatic steatosis. Sci Rep 2016;6:29352.
42. Wu X, Ge H, Baribault H, et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. J Lipid Res 2013;54:325-32.
43. Hasenfuss SC, Bakiri L, Thomsen MK, et al. Regulation of steatohepatitis and PPAR signaling by distinct AP-1 dimers. Cell Metab 2014;19:84-95.
44. Kim SC, Kim CK, Axe D, et al. All-trans-retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade. Hepatology 2014;59:1750-60.
45. Dong K, Li H, Zhang M, et al. Endoplasmic reticulum stress induces up-regulation of hepatic-Klotho expression through ATF4 signaling pathway. Biochem Biophys Res Commun 2015;459:300-5.
46. Hagel M, Miduturu C, Sheets M, et al. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discov 2015;5:424-37.
47. Bechmann LP, Gieseler RK, Sowa JP, et al. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int 2010;30:850-9.
48. Schaap FG, van der Gaag NA, Gouma DJ, et al. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009;49:1228-35.
49. Jung D, York JP, Wang L, et al. FXR-induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway. Pflugers Arch 2014;466:1011-19.
50. Naugler WE, Tarlow BD, Fedorov LM, et al. Fibroblast growth factor signaling controls liver size in mice with humanized livers. Gastroenterology 2015;149:728-40.e15.
51. Li Y, Zhang W, Doughtie A, et al. Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma. Oncotarget 2016;7:52329-39.
52. Nofer JR. Signal transduction by HDL: Agonists, receptors, and signaling cascades. Handb Exp Pharmacol 2015;224:229-56.
53. Collin de l'Hortet A, Zerrad-Saadi A, Prip-Buus C, et al. GH administration rescues fatty liver regeneration impairment by restoring GH/EGFR pathway deficiency. Endocrinology 2014;155:2545-54.